Finland

Pharmacovigilance activities in Finland are regulated by the Finnish Medicines Agency (Fimea) under EU pharmacovigilance legislation and EU GVP. The MAH must appoint an EU/EEA QPPV, maintain an EU/EEA PSMF, report ICSRs through EudraVigilance and meet applicable PSUR and RMP obligations. Fimea's notification form allows a possible contact person in Finland, but this role is not an automatically mandatory local QPPV. The system remains subject to inspection. As an EU/EEA jurisdiction, the EU pharmacovigilance framework applies to the EU QPPV and Union PSMF, EudraVigilance ICSR reporting, applicable PSURs, RMPs, signal management, quality-system audits and competent-authority inspections. MAHs should also check current national submission channels, contact arrangements and language requirements. BAUPHARMA supporting resources (operational context only, not national regulatory evidence): Difference in QPPV Nomination Between EU and KSA; PSMF Maintenance: Concept and Importance in Pharmacovigilance.